Oral sildenafil (Viagra™) in male erectile dysfunction: use, efficacy and safety profile in an unselected cohort presenting to a British district general hospital.

Affordable Access

Oral sildenafil (Viagra™) in male erectile dysfunction: use, efficacy and safety profile in an unselected cohort presenting to a British district general hospital.

Publisher
BioMed Central
Publication Date
Apr 18, 2002
Source
PMC
Keywords
Disciplines
  • Medicine
License
Unknown

Abstract

1471-2490-2-4.fm ral BioMed CentBMC Urology BMC Urology 2002, 2 xResearch article Oral sildenafil (Viagra™) in male erectile dysfunction: use, efficacy and safety profile in an unselected cohort presenting to a British district general hospital. Krishnamurthy Sairam*1, Elena Kulinskaya2, Damian Hanbury1, Gregory Boustead1 and Thomas McNicholas1 Address: 1Department of Urology, Lister Hospital Coreys Mill Lane, Stevenage SG1 4AB, UK and 2Reader in Medical Statistics, Health Reasearch & Development Support Unit (HRDSU) Faculty of Health & Human Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK E-mail: Krishnamurthy Sairam* - [email protected]; Elena Kulinskaya - [email protected]; Damian Hanbury - [email protected]; Gregory Boustead - [email protected]; Thomas McNicholas - [email protected] *Corresponding author Abstract Introduction: Sildenafil (Viagra®) is one of the drugs used in the first line therapy of male erectile dysfunction (MED). We have recorded outcomes, adverse events and acceptability of Sildenafil (Viagra) therapy in an unselected group of men presenting with ED to a British district general hospital. Methods: In this prospective observational study, 147 men with ED were seen since Oct 1999. Study patients were reviewed at 4, 12 and 52 weeks. All the patients filled the International Index of Erectile Function (IIEF) questionnaire and were asked about their willingness to pay (WTP) for treatment. Results: All suitable men accepted Viagra as first line therapy. 91% of our patients found sildenafil treatment successful. 80% of these patients were willing to continue with sildenafil therapy. Side effect profile of sildenafil was different in this study with much higher incidence of headache, dyspepsia, flushing and abnormal vision. 92% of men with ED expect to be treated by the NHS. Of those men eligible for treatment in the NHS, 30% qualify under the clinical categories and 18% under the 'distress' category. Only 55% of those w

Report this publication

Statistics

Seen <100 times